| Company Name: |
Nextpeptide Inc |
| Tel: |
+86-0571-81612335 +8613336028439 |
| Email: |
sales@nextpeptide.com |
| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
marketing1@energy-chemical.com |
BAY 60-2770
(BAY 602770) manufacturers
- BAY 60-2770
-
- $729.00
-
2026-07-16
- CAS:1027642-43-8
- Purity:
- Supply Ability: 10g
- BAY 60-2770
-
- $729.00
-
2026-07-15
- CAS:1027642-43-8
- Purity:
- Supply Ability: 10g
- BAY 60-2770
-
- $729.00
-
2025-10-28
- CAS:1027642-43-8
- Purity:
- Supply Ability: 10g
|
| | BAY 60-2770
(BAY 602770) Basic information |
| Product Name: | BAY 60-2770
(BAY 602770) | | Synonyms: | BAY 60-2770
(BAY 602770);BAY 60-2770;BAY 60-2770 >=98% (HPLC);Benzoic acid, 4-?[[(4-?carboxybutyl)?[2-?[5-?fluoro-?2-?[[4'-?(trifluoromethyl)?[1,?1'-?biphenyl]?-?4-?yl]?methoxy]?phenyl]?ethyl]?amino]?methyl]?- | | CAS: | 1027642-43-8 | | MF: | C35H33F4NO5 | | MW: | 623.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1027642-43-8.mol |  |
| | BAY 60-2770
(BAY 602770) Chemical Properties |
| Boiling point | 733.5±60.0 °C(Predicted) | | density | 1.288±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 2mg/mL, clear | | form | Solid | | pka | 4.02±0.10(Predicted) | | color | White to off-white | | InChIKey | CRQMDXFUKDWARU-UHFFFAOYSA-N | | SMILES | FC1=CC=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(CCN(CC4=CC=C(C(O)=O)C=C4)CCCCC(O)=O)=C1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | BAY 60-2770
(BAY 602770) Usage And Synthesis |
| Uses | BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect[1][2]. | | Biological Activity | BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect[1][2].
BAY 60-2770 (0.1-0.3 mg/Kg; p.o.) attenuates liver fibrosis in two rat models[1].BAY 60-2770 (1 mg/kg; p.o.; daily from the 10th to the 12th week) results in amelioration of bladder dysfunction in high-fat obese mice[2]. | | in vivo | BAY 60-2770 (0.1-0.3 mg/Kg; p.o.) attenuates liver fibrosis in two rat models[1].
BAY 60-2770 (1 mg/kg; p.o.; daily from the 10th to the 12th week) results in amelioration of bladder dysfunction in high-fat obese mice[2]. | Animal Model: | Obese mice[2] | | Dosage: | 1 mg/kg | | Administration: | p.o.; daily from the 10th to the 12th week | | Result: | Ameliorates detrusor dysfunction in obese mice.
|
| | References | [1]. Knorr A, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung. 2008;58(2):71-80.[2]. Leiria LO, et al. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J Urol. 2014 Feb;191(2):539-47. |
| | BAY 60-2770
(BAY 602770) Preparation Products And Raw materials |
|